AnaptysBio (NASDAQ:ANAB) versus Shattuck Labs (NASDAQ:STTK) Financial Contrast

Shattuck Labs (NASDAQ:STTK) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Shattuck Labs and AnaptysBio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1	0	9	2	3.00
AnaptysBio	1	3	11	0	2.67

Shattuck Labs presently has a consensus target price of $12.78, suggesting a potential upside of 106.09%. AnaptysBio has a consensus target price of $79.85, suggesting a potential upside of 47.56%. Given Shattuck Labs’ stronger consensus rating and higher possible upside, equities analysts clearly believe Shattuck Labs is more favorable than AnaptysBio.

Volatility & Risk

Shattuck Labs has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Institutional and Insider Ownership

58.7% of Shattuck Labs shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 31.5% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Shattuck Labs and AnaptysBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
AnaptysBio	-11.53%	N/A	-7.75%

Earnings & Valuation

This table compares Shattuck Labs and AnaptysBio”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1.00 million	622.25	-$48.81 million	($0.51)	-12.16
AnaptysBio	$234.60 million	6.83	-$13.23 million	($1.08)	-50.10

AnaptysBio has higher revenue and earnings than Shattuck Labs. AnaptysBio is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Summary

Shattuck Labs beats AnaptysBio on 9 of the 15 factors compared between the two stocks.

About Shattuck Labs

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

About AnaptysBio

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.